Keywords: abbott, 4th-qtr, profit, jumps, strong, sales, humira
Abbott's 4th-qtr profit jumps 28% on strong sales of Humira and divestment of spinal products unit
Article | 26 January 2009
US health care major Abbott Laboratories' fourth-quarter 2008 profit grew 28% year-on-year to $1.54 billion, or $0.98 per share, thanks to strong performance of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
